Yasunori Otowa1, Kota Yamashita1, Yu Saida1, Kazutoshi Yamamoto1, Jeffery R Brender1, Nallathamby Devasahayam1, Murali C. Krishna1, and Shun Kishimoto1
1National Cancer Institute, Bethesda, MD, United States
1National Cancer Institute, Bethesda, MD, United States
still in progress
Permeability of Gd-DPTA into SU.86.86 and MIA
Paca-2 tumors before treatment on Day 1 and 1 hour after treatment on Day 5
evaluated by DCE-MRI. (A) (B) (D) (E)Kinetics of the Gd-DTPA incorporation into
SU.86.86 or MIA Paca-2 tumors treated with combination of evofosfamide and GEM or vehicle. (C)
Comparison of Ktrans in combination of evofosfamide and GEM and control treated
tumor in SU86.86 tumor (*P=0.041). (F) Comparison of Ktrans in combination of evofosfamide and
GEM and control treated tumor in MIA Paca-2 tumor (***P<0.001).
Blood volume (%) changes calculated using
MRI with the blood pooling T2 contrast agent USPIO. (A) (B) (C) (D) The images
of blood volume on Day 1 and Day 5 in SU.86.86 tumors. (E) Comparison of blood
volume on Day 5 relative to Day1 in SU.86.86 tumors (**P=0.004). (F) (G)
(H) (I) The images of blood volume on Day 1 and Day 5 in MIA Paca-2 tumors. (E)
Comparison of blood volume on Day 5 relative to Day1 in MIA Paca-2 tumors (*P=0.036).